Navigation Links
LeClairRyan Adds Three Veteran Venture Capital Attorneys to San Francisco Office
Date:4/28/2011

SAN FRANCISCO, April 28, 2011 /PRNewswire/ -- LeClairRyan is pleased to announce the addition of three veteran venture capital attorneys to its San Francisco office.  Joining the firm in the corporate department are Eric K. Ferraro, Jeffrey T. Drake, and Jonathan T. Rubens, formerly of Bullivant Houser Bailey.

"We are excited to have Eric, Jeff and Jon join us," said San Francisco office leader Peter M. Hart.  "With their addition we are gaining significant legal experience and technology industry know-how, as well as expanding the depth and breadth of the corporate services we provide to clients in San Francisco."

Ferraro, who joins LeClairRyan as a shareholder, focuses his practice on the representation of private and public emerging and growth companies in the technology and digital media sectors as well as investors and financial services firms that focus on those industries. He advises clients in matters relating to entity formation and founder arrangements, corporate governance, seed and venture capital financing, employment and equity compensation, intellectual property protection, technology licensing and product distribution, mergers and acquisitions, public offerings, and SEC reporting and compliance.  He also has significant experience in executive compensation transactions, often representing CEOs and executive teams in high-value mergers and acquisitions.  Ferraro is a graduate of the Golden Gate University School of Law (J.D.) and the University of Vermont (B.A.).  

"With the addition of this West Coast team, LeClairRyan has added depth and important geographic reach to our representation of start-up and high growth companies," said Michael P. Drzal, leader of the firm's Venture Capital Practice Area Team.  "In addition to their depth of legal experience, technology industry knowledge, market awareness and business acumen, our San Francisco venture team brings with them a wealth of valuable connections to the West Coast angel and venture capital communities."

Drake, who joins the firm as a partner, has broad experience in securities, mergers and acquisitions, and commercial transactions in a variety of industries, particularly emerging growth, information technology, software and digital media.  His venture capital experience includes company-side and investor-side deals in both early stage and later rounds.  He is a graduate of the University of Idaho School of Law (J.D.) and the University of Idaho (B.S.).  

Rubens, also joining LeClairRyan as a partner, focuses his practice on the representation of entrepreneurs and investors in new venture formation, equity financings, mergers and acquisitions, and commercial loan transactions.  He also advises businesses on a variety of commercial transactions, intellectual property, data security and privacy issues. Rubens is a graduate of the University of California, Los Angeles (J.D.) and Dartmouth College (B.A.).  

About LeClairRyan

LeClairRyan's San Francisco office, established in 2008 through a merger with Wright, Robinson, Osthimer & Tatum, currently employs 27 attorneys and professional staff members. Founded in 1988, the firm provides business counsel and client representation in corporate law and high-stakes litigation. LeClairRyan boasts a roster of approximately 330 attorneys, representing a wide variety of clients across the nation, from offices in California, Connecticut, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Virginia and Washington, D.C. For more information about LeClairRyan, visit www.leclairryan.com.


'/>"/>
SOURCE LeClairRyan
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
2. FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
3. American Laser Centers Opens Three Minneapolis-St. Paul Area Clinics
4. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
5. ViroPharma to Present at Three September Healthcare Conferences
6. Spherics, Inc. Presented Three Key Technologies (BIOROD(TM), BIOGIT(TM), and SPHEROMER(TM)) at the 35th Annual Meeting of Controlled Release Society
7. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
8. ViroPharma to Present at Three October Healthcare Conferences
9. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
10. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
11. NicOx Reports Results for the First Three Quarters of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):